[
  {
    "ts": null,
    "headline": "Medtronic Announces Pricing of €1.5 Billion of Senior Notes",
    "summary": "Medtronic plc (the \"Company\") (NYSE: MDT) announced today that its wholly-owned indirect subsidiary, Medtronic, Inc., has priced an offering (the \"Offering\") of €750,000,000 principal amount of 2.950% senior notes due 2030 and €750,000,000 principal amount of 4.200% senior notes due 2045 (collectively, the \"Notes\"). All of Medtronic, Inc.'s obligations under the Notes will be fully and unconditionally guaranteed by the Company and Medtronic Global Holdings S.C.A. (\"Medtronic Luxco\"), a wholly-ow",
    "url": "https://finnhub.io/api/news?id=7adb074b7ffa455bb396694a1a2977fee0465d70e1afd074be70ccb4ec4c6d66",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757976060,
      "headline": "Medtronic Announces Pricing of €1.5 Billion of Senior Notes",
      "id": 136768129,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MDT",
      "source": "Yahoo",
      "summary": "Medtronic plc (the \"Company\") (NYSE: MDT) announced today that its wholly-owned indirect subsidiary, Medtronic, Inc., has priced an offering (the \"Offering\") of €750,000,000 principal amount of 2.950% senior notes due 2030 and €750,000,000 principal amount of 4.200% senior notes due 2045 (collectively, the \"Notes\"). All of Medtronic, Inc.'s obligations under the Notes will be fully and unconditionally guaranteed by the Company and Medtronic Global Holdings S.C.A. (\"Medtronic Luxco\"), a wholly-ow",
      "url": "https://finnhub.io/api/news?id=7adb074b7ffa455bb396694a1a2977fee0465d70e1afd074be70ccb4ec4c6d66"
    }
  },
  {
    "ts": null,
    "headline": "Medtronic (MDT) Launches Global Study On Novel Heart Failure Treatment",
    "summary": "Medtronic (MDT) has recently initiated the ELEVATE-HFpEF study focusing on heart failure treatment, which, alongside other product developments and strategic initiatives, coincides with a positive quarter-end price movement of 9%. This period saw advancements such as the launch of the Hugo™ robotic-assisted surgery system and FDA approval for the MiniMed™ 780G system, which likely supported investor sentiment. The broader market trend was upward, with indexes reaching record highs amid...",
    "url": "https://finnhub.io/api/news?id=1a65ebe8dbe59bfecaa9f5ff2b8eab7b05c8755a062e5132ed788247308ff5d0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757960335,
      "headline": "Medtronic (MDT) Launches Global Study On Novel Heart Failure Treatment",
      "id": 136766028,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MDT",
      "source": "Yahoo",
      "summary": "Medtronic (MDT) has recently initiated the ELEVATE-HFpEF study focusing on heart failure treatment, which, alongside other product developments and strategic initiatives, coincides with a positive quarter-end price movement of 9%. This period saw advancements such as the launch of the Hugo™ robotic-assisted surgery system and FDA approval for the MiniMed™ 780G system, which likely supported investor sentiment. The broader market trend was upward, with indexes reaching record highs amid...",
      "url": "https://finnhub.io/api/news?id=1a65ebe8dbe59bfecaa9f5ff2b8eab7b05c8755a062e5132ed788247308ff5d0"
    }
  },
  {
    "ts": null,
    "headline": "ISRG Stock Down More than 13% in 3 Months: How to Play the Stock?",
    "summary": "Intuitive Surgical shares are down 13% in three months as margin pressures weigh on the stock, but strong procedure growth keeps its long-term story intact.",
    "url": "https://finnhub.io/api/news?id=cca0486fc53938ef097cec7030608c9d3bf3c7608978ce5de4072823272d5878",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757944860,
      "headline": "ISRG Stock Down More than 13% in 3 Months: How to Play the Stock?",
      "id": 136750206,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MDT",
      "source": "Yahoo",
      "summary": "Intuitive Surgical shares are down 13% in three months as margin pressures weigh on the stock, but strong procedure growth keeps its long-term story intact.",
      "url": "https://finnhub.io/api/news?id=cca0486fc53938ef097cec7030608c9d3bf3c7608978ce5de4072823272d5878"
    }
  },
  {
    "ts": null,
    "headline": "Medtronic initiates global pivotal study of cardiac pacing in a new patient population",
    "summary": "Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced the initiation of a pivotal study evaluating the use of elevated and personalized cardiac pacing rates for the treatment of patients with Heart Failure with preserved Ejection Fraction (ELEVATE-HFpEF, NCT06678841). Physicians routinely use pacing therapy to treat patients whose hearts beat too slowly (bradycardia). This study, however, will investigate a potential novel treatment for patients with HFpEF by using",
    "url": "https://finnhub.io/api/news?id=4a734d05e284b6fd397e66719535c6a0e4f06749eae9318e4b2b3fa75e0c6684",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757944800,
      "headline": "Medtronic initiates global pivotal study of cardiac pacing in a new patient population",
      "id": 136749676,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MDT",
      "source": "Yahoo",
      "summary": "Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced the initiation of a pivotal study evaluating the use of elevated and personalized cardiac pacing rates for the treatment of patients with Heart Failure with preserved Ejection Fraction (ELEVATE-HFpEF, NCT06678841). Physicians routinely use pacing therapy to treat patients whose hearts beat too slowly (bradycardia). This study, however, will investigate a potential novel treatment for patients with HFpEF by using",
      "url": "https://finnhub.io/api/news?id=4a734d05e284b6fd397e66719535c6a0e4f06749eae9318e4b2b3fa75e0c6684"
    }
  },
  {
    "ts": null,
    "headline": "Is Medtronic’s 17% Rally Justified After Strong Earnings and Bullish Guidance?",
    "summary": "Thinking about what to do with Medtronic stock? You’re not alone. If you’re looking to make a move, or just want to know whether to hang tight, recent market signals have brought Medtronic back to the head of a lot of investor watchlists. With a steady closing price of $94.03, the stock has edged up by 1.1% over both the past week and the last 30 days. The bigger story, however, is a 17.2% rise year-to-date and a 7.8% bump over the past year. This suggests renewed confidence and a degree of...",
    "url": "https://finnhub.io/api/news?id=86c536c13ec2c21863ab1cf65ff4c54d1354ec958230bc6ef3ddf1683fbac07d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757936303,
      "headline": "Is Medtronic’s 17% Rally Justified After Strong Earnings and Bullish Guidance?",
      "id": 136749677,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MDT",
      "source": "Yahoo",
      "summary": "Thinking about what to do with Medtronic stock? You’re not alone. If you’re looking to make a move, or just want to know whether to hang tight, recent market signals have brought Medtronic back to the head of a lot of investor watchlists. With a steady closing price of $94.03, the stock has edged up by 1.1% over both the past week and the last 30 days. The bigger story, however, is a 17.2% rise year-to-date and a 7.8% bump over the past year. This suggests renewed confidence and a degree of...",
      "url": "https://finnhub.io/api/news?id=86c536c13ec2c21863ab1cf65ff4c54d1354ec958230bc6ef3ddf1683fbac07d"
    }
  },
  {
    "ts": null,
    "headline": "Opportunities in the Home Infusion Therapy Market 2025-2035 Featuring Strategic Analysis of Baxter International, B. Braun Melsungen, Fresenius Kabi, Medtronic, Terumo and More",
    "summary": "The market offers opportunities through increasing adoption due to rising chronic diseases, telehealth integration, and technological advancements. However, reimbursement challenges persist. North America leads due to favorable policies and demographics. Competitive growth is driven by innovation and market expansion.Dublin, Sept. 15, 2025 (GLOBE NEWSWIRE) -- The \"Home Infusion Therapy Market by Product Type, Application, Service Model - Global Market Size, Segmental Analysis, Regional Overview,",
    "url": "https://finnhub.io/api/news?id=fcd559ef7c05645f8cea9f067f657a0362e29bf5aba91a1b2110473dcc9dc00b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757934480,
      "headline": "Opportunities in the Home Infusion Therapy Market 2025-2035 Featuring Strategic Analysis of Baxter International, B. Braun Melsungen, Fresenius Kabi, Medtronic, Terumo and More",
      "id": 136749678,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MDT",
      "source": "Yahoo",
      "summary": "The market offers opportunities through increasing adoption due to rising chronic diseases, telehealth integration, and technological advancements. However, reimbursement challenges persist. North America leads due to favorable policies and demographics. Competitive growth is driven by innovation and market expansion.Dublin, Sept. 15, 2025 (GLOBE NEWSWIRE) -- The \"Home Infusion Therapy Market by Product Type, Application, Service Model - Global Market Size, Segmental Analysis, Regional Overview,",
      "url": "https://finnhub.io/api/news?id=fcd559ef7c05645f8cea9f067f657a0362e29bf5aba91a1b2110473dcc9dc00b"
    }
  }
]